The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*Yan Zhao, J Zhang, Xing‐Hua Gao et al.|British Journal of Dermatology|2021Cited by 73
Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III StudyYan Zhao, Liming Wu, Qianjin Lu et al.|International Journal of Dermatology and Venereology|2022Cited by 4